MedTrace Logo

Avatrombopag for Platelet Recovery Post-UCBT in Patients With Bone Marrow Failure Disease

NCT05823376 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2024-12-31

No results posted yet for this study

Summary

To evaluate the efficacy and safety of Avatrombopag for platelet recovery after unrelated cord blood transplantation (UCBT) in patients with bone marrow failure disease

Conditions

  • Platelet Recovery After Umbilical Cord Blood Transplantation

Interventions

DRUG

Avatrombopag

Indications for drug reduction and withdrawal: excluding blood transfusion factors, the reduction will be 20mg/d when PLT≥50×10\^9/L; Drug administration will be stopped when PLT≥100×10\^9/L.

Sponsors & Collaborators

  • Anhui Provincial Hospital

    lead OTHER_GOV

Principal Investigators

  • Xiaoyu Zhu, ph.D · The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-04
Primary Completion
2025-01-31
Completion
2025-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05823376 on ClinicalTrials.gov